Patrys Limited (PAB.AX)
AUD 0.0
(0.0%)
AUD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 691.36 Thousand AUD | 0.65% |
| 2023 | 686.89 Thousand AUD | 26.54% |
| 2022 | 542.82 Thousand AUD | -36.13% |
| 2021 | 849.86 Thousand AUD | 70.52% |
| 2020 | 498.38 Thousand AUD | -21.81% |
| 2019 | 637.42 Thousand AUD | -6.5% |
| 2018 | 681.77 Thousand AUD | 37.58% |
| 2017 | 495.53 Thousand AUD | -20.11% |
| 2016 | 620.25 Thousand AUD | -22.69% |
| 2015 | 802.28 Thousand AUD | -66.28% |
| 2014 | 2.37 Million AUD | 120.06% |
| 2013 | 1.08 Million AUD | 17.99% |
| 2012 | 916.35 Thousand AUD | -33.63% |
| 2011 | 1.38 Million AUD | 28.55% |
| 2010 | 1.07 Million AUD | -26.41% |
| 2009 | 1.45 Million AUD | 65.44% |
| 2008 | 882.3 Thousand AUD | 0.0% |
| 2007 | - AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 584.22 Thousand AUD | 0.0% |
| 2024 FY | 691.36 Thousand AUD | 0.65% |
| 2024 Q4 | 691.36 Thousand AUD | 0.0% |
| 2023 Q4 | 686.89 Thousand AUD | 0.0% |
| 2023 FY | 686.89 Thousand AUD | 26.54% |
| 2023 Q2 | 1.7 Million AUD | 0.0% |
| 2022 Q4 | 542.82 Thousand AUD | 0.0% |
| 2022 FY | 542.82 Thousand AUD | -36.13% |
| 2022 Q2 | 3.7 Million AUD | 0.0% |
| 2021 FY | 849.86 Thousand AUD | 70.52% |
| 2021 Q2 | 579.91 Thousand AUD | 0.0% |
| 2021 Q4 | 849.86 Thousand AUD | 0.0% |
| 2020 Q2 | 535.64 Thousand AUD | 0.0% |
| 2020 FY | 498.38 Thousand AUD | -21.81% |
| 2020 Q4 | 498.38 Thousand AUD | 0.0% |
| 2019 Q4 | 637.42 Thousand AUD | 0.0% |
| 2019 FY | 637.42 Thousand AUD | -6.5% |
| 2019 Q2 | 527.92 Thousand AUD | 0.0% |
| 2018 FY | 681.77 Thousand AUD | 37.58% |
| 2018 Q2 | 584.77 Thousand AUD | 0.0% |
| 2018 Q4 | 681.77 Thousand AUD | 0.0% |
| 2017 Q4 | 495.53 Thousand AUD | 0.0% |
| 2017 FY | 495.53 Thousand AUD | -20.11% |
| 2017 Q2 | 585.54 Thousand AUD | 0.0% |
| 2016 FY | 620.25 Thousand AUD | -22.69% |
| 2016 Q4 | 620.25 Thousand AUD | 0.0% |
| 2016 Q2 | 683.55 Thousand AUD | 0.0% |
| 2015 Q2 | 1.51 Million AUD | 0.0% |
| 2015 FY | 802.28 Thousand AUD | -66.28% |
| 2015 Q4 | 802.28 Thousand AUD | 0.0% |
| 2014 FY | 2.37 Million AUD | 120.06% |
| 2014 Q4 | 2.37 Million AUD | 0.0% |
| 2014 Q2 | 2.4 Million AUD | 0.0% |
| 2013 Q3 | 1.04 Million AUD | 24.48% |
| 2013 FY | 1.08 Million AUD | 17.99% |
| 2013 Q4 | 1.08 Million AUD | 3.52% |
| 2013 Q1 | 839.1 Thousand AUD | -8.43% |
| 2013 Q2 | 839.1 Thousand AUD | 0.0% |
| 2012 Q4 | 916.35 Thousand AUD | 0.0% |
| 2012 FY | 916.35 Thousand AUD | -33.63% |
| 2011 Q4 | 1.38 Million AUD | 0.0% |
| 2011 FY | 1.38 Million AUD | 28.55% |
| 2010 Q4 | 1.07 Million AUD | 0.0% |
| 2010 FY | 1.07 Million AUD | -26.41% |
| 2009 Q4 | 1.45 Million AUD | 0.0% |
| 2009 FY | 1.45 Million AUD | 65.44% |
| 2008 Q4 | 882.3 Thousand AUD | 0.0% |
| 2008 FY | 882.3 Thousand AUD | 0.0% |
| 2007 FY | - AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AdAlta Limited | 3.54 Million AUD | 80.484% |
| Acrux Limited | 5.68 Million AUD | 87.843% |
| Actinogen Medical Limited | 1.61 Million AUD | 57.201% |
| AnteoTech Limited | 4.07 Million AUD | 83.035% |
| Argenica Therapeutics Limited | 2.42 Million AUD | 71.51% |
| Arovella Therapeutics Limited | 2.05 Million AUD | 66.384% |
| Anatara Lifesciences Ltd | 306.84 Thousand AUD | -125.311% |
| Alterity Therapeutics Limited | 5.42 Million AUD | 87.258% |
| Amplia Therapeutics Limited | 3.42 Million AUD | 79.825% |
| Avecho Biotechnology Limited | 941.54 Thousand AUD | 26.571% |
| Bio-Gene Technology Limited | 368.44 Thousand AUD | -87.644% |
| Biome Australia Limited | 5.37 Million AUD | 87.133% |
| Biotron Limited | 737.5 Thousand AUD | 6.257% |
| Botanix Pharmaceuticals Limited | 3.73 Million AUD | 81.475% |
| BTC Health Limited | 203.94 Thousand AUD | -238.991% |
| Chimeric Therapeutics Limited | 12.8 Million AUD | 94.6% |
| CSL Limited | 27.88 Billion AUD | 99.998% |
| Clarity Pharmaceuticals Ltd | 8.33 Million AUD | 91.702% |
| Clinuvel Pharmaceuticals Limited | 28.11 Million AUD | 97.541% |
| Cynata Therapeutics Limited | 1.17 Million AUD | 40.962% |
| Dimerix Limited | 13.89 Million AUD | 95.024% |
| EZZ Life Science Holdings Limited | 4.22 Million AUD | 83.652% |
| Hexima Limited | 248.67 Thousand AUD | -178.025% |
| Island Pharmaceuticals Limited | 1.04 Million AUD | 33.88% |
| Immuron Limited | 2.84 Million AUD | 75.661% |
| Immutep Limited | 10.97 Million AUD | 93.703% |
| Imugene Limited | 33.14 Million AUD | 97.914% |
| Invex Therapeutics Ltd | 431.63 Thousand AUD | -60.175% |
| Memphasys Limited | 5.59 Million AUD | 87.637% |
| Nanollose Limited | 465.64 Thousand AUD | -48.475% |
| Neuren Pharmaceuticals Limited | 42.76 Million AUD | 98.383% |
| Noxopharm Limited | 1.28 Million AUD | 46.348% |
| NeuroScientific Biopharmaceuticals Limited | 85.68 Thousand AUD | -706.887% |
| Nyrada Inc. | 855.63 Thousand AUD | 19.198% |
| Orthocell Limited | 22.08 Million AUD | 96.869% |
| PharmAust Limited | 896.6 Thousand AUD | 22.891% |
| Paradigm Biopharmaceuticals Limited | 3.58 Million AUD | 80.712% |
| Proteomics International Laboratories Limited | 1.62 Million AUD | 57.479% |
| Prescient Therapeutics Limited | 2.32 Million AUD | 70.271% |
| PYC Therapeutics Limited | 10.18 Million AUD | 93.211% |
| Race Oncology Limited | 1.91 Million AUD | 63.924% |
| Radiopharm Theranostics Limited | 44.68 Million AUD | 98.453% |
| Recce Pharmaceuticals Ltd | 15.89 Million AUD | 95.65% |
| Starpharma Holdings Limited | 8.69 Million AUD | 92.051% |
| Telix Pharmaceuticals Limited | 249.39 Million AUD | 99.723% |
| Tissue Repair Ltd | 1.35 Million AUD | 48.822% |
| Zelira Therapeutics Limited | 9.35 Million AUD | 92.611% |